and it is looking to zuranolone for meaningful growth. Biogen arguably has the most riding on zuranolone however, having stumped up $1.525 billion upfront for rights to the drug and another Sage ...

Potential delays in regulatory approvals for key pipeline products, including subcutaneous formulations of LEQEMBI, were noted as risks to growth projections. Biogen demonstrated solid progress in ...

This positioning may be influenced by factors such as growth expectations or operational capacity. Negative Revenue Trend: Examining Biogen's financials over 3 months reveals challenges.

Biogen Inc (NASDAQ:BIIB) has successfully reduced operating expenses, freeing up resources for growth investments, resulting in improved cash flow. Revenue from new product launches in 2024 more ...